Table 1.
Baseline characteristics of the full analysis set
| IPV (n=206) | 1/3 IPV-Al (n=206) | 1/5 IPV-Al (n=206) | 1/10 IPV-Al (n=206) | ||
|---|---|---|---|---|---|
| Sex | |||||
| Female | 109 (52·9) | 99 (48·1) | 100 (48·5) | 109 (52·9) | |
| Male | 97 (47·1) | 107 (51·9) | 106 (51·5) | 97 (47·1) | |
| Age (days) | 44·3 (2·1) | 44·0 (2·1) | 44·2 (2·1) | 44·0 (2·1) | |
| Height (cm) | 55·4 (3·0) | 55·1 (2·3) | 55·2 (2·5) | 55·0 (2·6) | |
| Weight (g) | 4797 (581) | 4743 (502) | 4831 (541) | 4732 (557) | |
| Birthweight (g) | 3195 (407) | 3225 (381) | 3236 (412) | 3180 (386) | |
Data are n (%) or mean (SD), unless otherwise indicated. Data are for number of participants in the safety analysis set. IPV=inactivated polio vaccine. IPV-Al=IPV adsorbed to aluminium hydroxide.